UPDATE: Morgan Stanley Reiterates On Albany Molecular Research On Model/Valuation Update

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Albany Molecular Research AMRI, and raised the price target from $19.00 to $21.00. In the report, Morgan Stanley noted, “Following recent OsoBio acq. we update ests & raise PT to $21. With M&A strategy tracking ahead of expectations, we have increased confidence in bull case unfolding & highlight AMRI as a top pick in our coverage for 2H14.” Albany Molecular Research closed on Tuesday at $17.44.